On the safety side, six patients treated across all three doses of VX-809 during the one-month monotherapy stage discontinued due to adverse events. Reasons for discontinuation included rash and "chest tightness," according to Boyle, who was surrounded by Wall Street investors after his presentation.
"We're going to pay attention to that," said Boyle from the middle of the Wall Street scrum, referring to the adverse events observed in the trial. Boyle added that one of his patients reported "mild to moderate" chest tightness but it didn't cause her to drop out of the study.
"I viewed it as a sign that something was going on, probably a sign of an effect," he said.
In a separate interview, I asked Boyle for his overall impressions of the VX-809/Kalydeco data:"Overall, I'm encouraged and excited. When I first got the
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.